While a number of structural and cellular abnormalities occur in the islet of Langerhans in diabetes, and in particular in type 2 diabetes, the focus has been mostly on the insulin producing β-cells and only more recently on glucagon producing α-and δ-cells. There is ample evidence that in type 2 diabetes mellitus (T2DM), in addition to a progressive decline in β-cell function and associated insulin resistance in a number of insulin-sensitive tissues, alterations in glucagon secretion are also present and may play an important role in the pathogenesis of hyperglycemia both in the fasting and in the postprandial state. Recently, a number of studies have showed that there are also functional and structural alterations in glucagon-producing α-cells and somatostatin-producing δ-cells. Thus, it is becoming increasingly clear that multiple cellular alterations of multiple cell types occur, which adds even more complexity to our understanding of the pathophysiology of this common and severe disease. We believe that persistent efforts to increase the understanding of the pathophysiology of hormone secretion in the islets of Langerhans will also improve our capability to better prevent and treat diabetes mellitus. 
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| ISLET OF LANGERHANS CYTOARCHITECTURE IN NORMAL ADULT HUMAN PANCREAS AND NON-HUMAN PRIMATE PANCREAS
In that last 15 years, a number of studies have shown that cell distribution as well as the relative abundance of the different cell types in the islets of Langerhans is strikingly different in rodents (rats and mice) than in humans and non-human primates (baboons and monkeys). In adult 
"
The cytoarchitecture of the islets of Langerhans is profoundly heterogeneous in different portions of the human pancreas. 
| α-cells
In rodents, glucagon cells account for around 7% to 8% of all cells and are present in the periphery of the islet, 3 and they are scattered throughout the human and non-human primate islet. 
| δ-cells
In rodents, δ-cells are the minority, and they are located at the periphery of the islets. The islet of Langerhans cytoarchitecture in rodents (mouse and rats) is profoundly different from the one of non-human and human primates. In rodents, β-cells are positioned in the central core of the islet, surrounded by α-and δ-cells in the periphery of the islets. In human and nonhuman primates, β-cells are the majority of the cells in the islet but are mingled with α-and δ-cells and have extensive direct contacts with them, suggesting potent paracrine interactions.
" 2 | ISLET OF LANGERHANS REMODELLING IN HUMAN AND NON-HUMAN PRIMATE T2DM
At the onset of type 2 diabetes mellitus (T2DM) there are no specific gross changes of the pancreas, while after a long period of the disease, there is a decrease from 1% to 40% of the total pancreatic weight.
Histologically, at the onset of disease the islet cell mass is more or less normal, while in patients with long-standing type 2 diabetes, several morphological alterations can be observed.
| β-and α-cells
In long-standing type 2 diabetes, the normal distribution and the number of islet cells are altered. In particular, β-cell volume is reduced while and chimpanzees show 98% to 99% identity at the protein levels with humans as well as developing obesity, insulin resistance and substantially the same endocrine diseases and metabolic diseases, including type 2 diabetes mellitus, with the same islet alterations.
11-16
An increase of apoptosis in β-cells has been shown together with a relative/absolute increase number of α-cells. Electron microscopy of human pancreatic islet of Langerhans in type 2 diabetes mellitus (T2DM) human subject. A, β-cell contains a large deposit of amyloid (blue star), is heavily vacuolated and partially degranulated. B, Another β-cell contains a large vacuole (red asterisk) and mitochondria with deranged cristae (green star). C, δ-cell contains a large vacuole (red asterisk), a dilated endoplasmic reticulum (dark red star) and is heavily degranulated. D, α-cell is ultrastructurally normal and well granulated marker of dedifferentiating β-cells. [22] [23] [24] Consistent with the possibility that transdifferentiation occurs in T2DM pancreatic islets, we have also observed cells that express both insulin as well as glucagon in the same cell in the islets of Langerhans of patients with T2DM
( Figure 5 ).
| δ-cells
Interestingly, the number of δ-cells is reduced in the pancreas of human T2DM as compared with a normal glucose tolerant (NGT) control ( Figure 6C,D) . In addition to the alterations observed in β-and α-cells in humans and non-human primates, it has been recently showed that somatostatin-producing δ-cells are also reduced by apoptotic mechanisms in the islets of type 2 diabetic baboons and that these alterations also correlate inversely with baseline glucagon levels, suggesting that a reduction of somatostatin production might be germane to increased glucagon release in diabetic baboons. 25 The findings of reduced β-cell mass (generally ranging from 30%
to 60% in the scientific literature), reduced δ-cell mass and relatively unchanged absolute mass of α-cells, have also been documented in a recent study in which insulin, glucagon and somatostatin content have been evaluated in the pancreas of T2DM subjects. In this study, insulin content was decreased by 35%, glucagon was unchanged and somatostatin content was 29% lower in T2DM as compared to NGT subjects, consistent with previously published studies.
11,25
We have also observed reduced δ-cells in pancreases of humans with long-standing type 2 diabetes (Figure 6C,D) . By employing double immunohistochemistry as well as triple florescence immunostaining and confocal microscopy with tunel/insulin/somatostatin, we have also demonstrated the existence of δ-cell apoptosis (Figures 7 and 8) .
EM studies have also demonstrated that in the pancreas of T2DM
patients, δ-cells have a number of ultrastructural alterations, including degranulation and vacuolization and nuclei with condensed chromatin, which are sign of cell stress as well as apoptotic features (Figure 4 ).
These new findings support a concurrent role of δ-cells in the pathogenesis of type 2 diabetes. Considering the well-known negative paracrine effect of somatostatin on α-cell secretion, the reduction of δ-cells, together with the relative or absolute increase in α-cell volume, can also play a role in the islet disfunction of T2DM. Considering this paracrine connection, the reduction on δ-cells together with a reduction in somatostatin secretion, may result in the lack of glucagon secretion inhibition by the α-cells.
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"
There are a number of alterations in the cytoarchitecture of the islets of Langerhans in T2DM, including a marked reduction of β-cells (up to 70%), a reduction in δ-cells (around 25%-30%) and relative/(absolute?) increase in α-cells. 
| Amyloid
The characteristic islet alteration is represented by amyloid deposition which was first described by Opie 27 and subsequently called "hyalini- showing islet amyloidosis range from 40% to 100%. 11, 19, 34, 35 Interestingly also, and consistent with the possibility that amyloid deposition and its damaging action occurs in the pancreas of humans with diabetes because of increased insulin demand and subsequent increased IAPP secretion, it has been observed that amyloid deposition occurs after human islet transplantation in humans as well as in streptozotocin diabetic nude mice receiving a suboptimal number of human islets of Langerhans.
36,37
"
Amyloid deposition, through self aggregation and precipitation of IAPP in β-cells, is a key pathological process in the pancreatic islets of Langerhans in the T2DM as well as after pancreatic islet transplantation in humans with type 1 diabetes mellitus. 
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